Craig Hallum Lowers biote (NASDAQ:BTMD) Price Target to $8.00

biote (NASDAQ:BTMD) had its price target decreased by equities researchers at Craig Hallum from $12.00 to $8.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s price objective points to a potential upside of 112.77% from the stock’s current price.

biote Stock Performance

BTMD opened at $3.76 on Thursday. The firm has a 50 day moving average price of $4.96 and a 200 day moving average price of $5.55. The company has a market cap of $204.31 million, a PE ratio of 14.46 and a beta of 1.07. biote has a 1 year low of $3.04 and a 1 year high of $8.44.

Institutional Trading of biote

Several large investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new stake in biote in the fourth quarter valued at approximately $69,000. Squarepoint Ops LLC acquired a new stake in biote in the fourth quarter valued at approximately $115,000. Millennium Management LLC acquired a new stake in biote in the fourth quarter valued at approximately $414,000. Lazard Asset Management LLC acquired a new stake in biote in the fourth quarter valued at approximately $139,000. Finally, Deutsche Bank AG grew its position in biote by 4,987.5% in the fourth quarter. Deutsche Bank AG now owns 31,441 shares of the company’s stock valued at $194,000 after acquiring an additional 30,823 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.